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Background: Insomnia, defined as repeated difficulties getting or staying asleep, is common in the general population.
Such sleep difficulties are a problem in their own right, but increasingly it is being recognised that they may also be a
contributory factor in the development of a wide range of mental health problems. Our focus is upon the relationship
between insomnia and psychotic experiences, such as paranoia and hallucinations. Psychotic experiences commonly
occur in mild forms in the general population and have been linked to disrupted sleep. These psychotic-like experiences
raise the risk of development of a clinical disorder. Our aim is to reduce insomnia in a large general population group,
and examine the effect on paranoia and hallucinations at the age when mental health problems typically emerge. The
primary hypotheses are that cognitive behaviour therapy (CBT) for insomnia will reduce insomnia and also levels of
paranoia and hallucinations. The theoretical links will be substantiated by a planned mediation analysis. Improvements in
a number of other mental health outcomes are also predicted.
Methods/Design: We will carry out a parallel group, randomised controlled trial of 2,614 students with insomnia
in universities across the UK. In the Oxford Access for Students Improving Sleep (OASIS) trial, participants will be
randomised to digital CBT for insomnia (in addition to treatment as usual) or treatment as usual. Online assessments
will take place at zero, three, 10 (post-treatment), and 22 (follow-up) weeks. Primary outcomes are insomnia and
psychotic-like experiences (paranoia or hallucinatory experiences) at 10 weeks. Secondary outcomes are levels of mania,
depression, anxiety, nightmares, psychological wellbeing, and the development of mental health disorders. All main
analyses will be carried out at the end of the last follow-up assessment and will be based on the intention-to-treat
principle. The trial is funded by the Wellcome Trust.
Discussion: This study will be the first large-scale causal test of the relationship between sleep disturbance and psychotic
experiences. It will provide evidence concerning the clinical effects of treating insomnia in young adults.
Trial registration: This trial was registered with Current Controlled Trials (identifier: ISRCTN61272251) on 29 January 2015.
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Disrupted sleep is increasingly recognised as a contribu-
tory causal factor in the occurrence of many mental health
problems [1–3]. This is based not only upon the know-
ledge that sleep promotes better daytime functioning, but
that sleep processes and mental health disorders have
overlapping mechanisms. Our particular interest is in the
potential causal relationship between poor sleep and
psychotic experiences, such as paranoia and hallucina-
tions. A key approach to establishing a causal relationship,
called an interventionist causal model [4], is to manipulate
a putative causal factor and assess the effect on the out-
come of interest. In the current trial we aim to improve
sleep in people with insomnia in order to examine the ef-
fect on psychotic-like experiences. This approach there-
fore informs both theory and clinical practice.
Insomnia
The most common form of sleep disruption is insomnia,
which principally comprises sustained difficulties in initi-
ating or maintaining sleep. Insomnia is a common psycho-
logical disorder: at any one time, approximately one third
of the general population experience symptoms of insom-
nia [5, 6], whilst around 6 % of adults will currently meet
diagnostic criteria for insomnia disorder [5, 7]. Just as for
other mental health problems, there is a spectrum of se-
verity in the general population. Although prevalence is
high, natural remission appears to be low. In one patient
study, 74 % of individuals continued to have insomnia one
year later, and 46 % reported insomnia persisting for over
three years [8]. Importantly, meta-analyses report moder-
ate to large sustained improvements in insomnia following
treatment with cognitive behavioural therapy (CBT) for
insomnia [9–11]. Thus clinical guidelines recommend the
use of CBT for the treatment of insomnia [12, 13].
Psychotic experiences
A focus upon explaining individual psychotic experi-
ences has gained increased interest because of evidence
that the main diagnoses of psychosis, such as schizo-
phrenia, schizoaffective disorder, and delusional dis-
order, do not capture single disorders. The empirical
research indicates that within these diagnoses are mul-
tiple (relatively) independent experiences, such as para-
noia, hallucinations, grandiosity, thought disorder, and
anhedonia [14–16]. Furthermore, these problems are
not confined to clinical disorders. There is a spectrum
of severity in the general population of each of these in-
dividual psychotic experiences. For example, many
people have a few paranoid thoughts, and a few people
have many severe paranoid thoughts [17–19]. Whilst
these psychotic like experiences are often transitory,
their persistence over time constitutes a risk factor for
developing later psychosis [20].Insomnia and psychotic experiences
In cross-sectional and longitudinal studies, paranoia in
particular [21–24], but also hallucinations [25] have been
linked to insomnia. Circadian rhythm disruption has
been shown to be common in patients diagnosed with
schizophrenia [26–28]. Importantly, a recent twin study
of adolescents indicates that insomnia and psychotic ex-
periences share overlap in genetic and environmental
aetiology [25]. Applying the interventionist-causal model
approach, we showed in a pilot case series that treating
insomnia with CBT in patients with persecutory delu-
sions (that is, severe paranoia) is associated with reduc-
tions in insomnia, paranoia, and anomalous perceptual
experiences [29]. This is consistent with insomnia having
a contributory causal role in psychotic experiences. De-
veloping this work, we are completing a randomised
controlled trial testing CBT for insomnia in 50 patients
with delusions and hallucinations [30].
In the current trial we set out to test the effects of
treating insomnia on psychotic-like experiences (and
other mental health outcomes) in students attending
university. A systematic literature search indicated that
there had been no such similar tests. The benefit of
choosing this participant group to test the hypotheses is
twofold. First, it will enable recruitment of a large sam-
ple to test the hypotheses robustly. Circular emails will
be sent at many UK universities, and students will be
able to carry out the study online without face-to-face
contact with the research team. Second, mental health
problems such as psychosis typically have their first on-
set in late adolescence or /early adulthood [31], and
therefore university students are at a vulnerable, and
hence important, age to study. We will treat insomnia
using the recommended approach of CBT. The CBT
course will be delivered entirely online using computer
or smartphone [32, 33]. It will be compared with treat-
ment as usual, rather than an attention control or active
control, because our central aim is to manipulate sleep
to test the effects on mental health problems, that is, to
conduct a mechanistic test. We therefore require one
group to exhibit a change sleep patterns, and one group
to show less change in sleep patterns. Furthermore, the
CBT intervention to be used has already been shown to
be of much greater efficacy than an attention control
condition [32].
The primary hypotheses for the trial are:
1. The digital CBT intervention will reduce insomnia
by the end of treatment (10 weeks).
2. The digital CBT intervention will reduce psychotic-
like experiences (paranoia and hallucinations) by the
end of treatment.
3. Changes in insomnia will mediate the changes in
psychotic-like experiences.
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1. The digital CBT intervention will reduce levels of
depression, anxiety, nightmares, and mania by the
end of treatment (10 weeks).
2. The digital CBT intervention will improve
psychological wellbeing by the end of treatment.
3. The effects of CBT will be maintained at the
scheduled follow-up assessment (22 weeks).
4. The digital CBT intervention will lead to the
occurrence of fewer mental health disorders during
the period of the trial, as assessed by screening tools
at 22 weeks for ultra-high risk of psychosis, bipolar
affective disorder, depression, and anxiety, and by
treatment by mental health services.
Methods/Design
Research design
The study is a parallel group, superiority, randomised con-
trolled trial of digital CBT in addition to treatment as usual
versus only treatment as usual. The trial design is sum-
marised in Fig. 1. The study will be carried out completely
online. Participants will carry out screening, informed con-
sent, assessments, allocation to condition, and interventionFig. 1 Summary of the trial design for the OASIS studyvia a computer programme specifically designed for the
trial. We will therefore run an internal pilot of 100 partici-
pants in order to check that the automated computer
system is running correctly. The study has received ethical
approval from the University of Oxford Medical Sciences
Inter-Divisional Ethics Committee (reference number:
MSD-IDREC-C2-2014-034). An information sheet is pro-
vided online, and informed consent is completed online be-
fore participation in the study can occur.
Participants
We will recruit 2,614 students from UK universities. The
inclusion criteria are: those with a positive screen for prob-
able insomnia disorder, as indicated by a score of 16 or
lower on the Sleep Condition Indicator (SCI) [34]; and be-
ing aged 18 or older. There are no exclusion criteria; we will
not omit participants who report no signs of psychotic-like
experiences because the dimensional measures of paranoia
and hallucinations will be endorsed to some extent by a
majority of participants, while we are also interested in
other mental health outcomes that will be relevant to all
participants (for example psychological wellbeing). Univer-
sities across the UK will be approached to take part. At
each university, participants will be recruited via email
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screening. Therefore many thousands of students at each
university taking part will receive an invite to take part in
screening for the study. Participants will not be recruited
via health settings.
Randomisation and allocation concealment
This study will use simple randomisation with an alloca-
tion ratio of 1:1, as recommended for large clinical trials
[35]. It will be carried out by the automated online system,
hence the research team will be unable to influence ran-
domisation, and have no access to future allocations.
Blinding
This will be a single blind trial. Assessments will be self-
reported and carried out online, and hence the research
team will be blind to outcomes during the trial. Partici-
pants will be informed of their randomisation outcome by
an automatic email, and hence they will not be blind to
treatment allocation. It is notable that the research team is
unlikely to have any contact with research participants,
and will therefore be unable to bias the allocation or as-
sessments. If participants do contact the team and reveal
the allocation, the absence of assessments carried out by
an assessor prevents assessments becoming unblinded.
Assessment points
Assessments will take place at the key assessment points
of 0 (baseline), three (mid-therapy), 10 (end of therapy),
and 22 weeks (follow-up). As an ethical consideration,
all the control participants will be provided with CBT at
23 weeks, once the 22-week follow-up assessment has
been conducted. We will therefore take this opportunity
to include a further follow-up at 33 weeks for all trial
participants (providing a potential replication of the
within group treatment effect).
Planned intervention
The CBT for insomnia intervention is delivered predomin-
ately via the internet. The delivery is structured into six ses-
sions, lasting an average of 20 minutes each. The course
takes a minimum of six weeks to complete, with sessions
unlocked weekly. Participants can move at a slower pace,
for up to a maximum of 12 weeks. All participants have to
at least start the programme online. Certain tools (such as
sleep diaries and relaxation audios) can also be accessed
using the web browser of any smartphone. All of the six
core sessions, sleep diaries, relaxation audios, and the
scheduling tool can also be accessed using an iOS app, but
this is only an option for participants who have an iPhone®.
The treatment content is based on CBT for insomnia man-
uals [36–38] and includes a behavioural component (sleep
restriction, stimulus control, and relaxation), a cognitive
component (paradoxical intention, cognitive restructuring,mindfulness, positive imagery, and putting the day to rest)
and an educational component (psycho-education and
sleep hygiene).
The programme is highly interactive, and content is
presented by an animated virtual therapist. Participants
make a time for the session and are prompted via email
and/or SMS if they do not ‘attend’. Participants complete
daily sleep diary information throughout the interven-
tion, which are used by the programme to provide tai-
lored, personalised help. Participants receive an email
and/or SMS reminder each morning to prompt them to
fill in their sleep diary. In addition, participants complete
a short questionnaire at the beginning of therapy to set
treatment goals. Throughout the course of therapy, par-
ticipants have access to a moderated online community
and an online library of information about sleep. Partici-
pants can view their online case file, which includes four
sections: a progress review, a reminder of strategies to
try out between sessions, an agreed sleep schedule, and a
list of further reading. The system provides online
analytics, which can be used to monitor adherence by
assessing how many sessions were completed and the
number of weeks to complete the course. Data from the
CBT programme show that 90 % of participants complete
the course within 10 weeks; participants will have access
to the intervention for up to 12 weeks. We note that treat-
ment as usual will actually comprise of no intervention at
all for the majority of participants, since they are not being
recruited from clinical services.
Outcome measures
Participants will receive an email prompt to complete the
assessments online. The order of the assessments will be
consistent across all participants and all time points. If
participants do not complete the questionnaire within two
days they will receive an email reminder. The full battery
of questionnaires comprises 118 questions in total. The
week three assessment is briefer, including only the key
measures, which total 44 questions.
The primary measure for insomnia is the SCI [34].
This is an eight-item measure. Scores can range from 0
to 32, with higher scores indicating better sleep. A clin-
ical cut off of less than 17 has been shown to correctly
identify 89 % of those with probable insomnia disorder.
The measure has good internal consistency (Cronbach’s
alpha = 0.86) [34]. We will use a version of the SCI that
includes one additional question regarding early morn-
ing waking.
The primary measure for paranoia will be the Green
et al. Paranoid Thoughts Scale (GPTS), Part B [39]. The
GPTS assesses persecutory ideation and the timeframe
used will be the past fortnight. The scale comprises 16
items, each rated on a one (not at all) to five (totally) scale.
The persecutory ideas sub-scale has excellent internal
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liability (correlation coefficient = 0.81), and good conver-
gent and criterion validity [39].
The Specific Psychotic Experiences Questionnaire (SPEQ)
- Hallucinations sub-scale [16] will be the primary outcome
for hallucinatory experiences. The scale is adapted from the
Cardiff Anomalous Perceptions Scale [40], and comprises
nine items measuring hallucinatory experiences across
a range of sensory modalities and has good internal
consistency, test re-test reliability, and convergent valid-
ity [16]. Participants will be asked to consider the period
of the past fortnight and the scale used for each item is
from zero (not at all) to five (more than once per day).
Secondary outcome measures for sleep include the In-
somnia Severity Index [41, 42] and the Disturbing Dreams
and Nightmare Severity Index [43]. We will also include
in the assessment one question concerning chronotype
from the Morningness-Eveningness Questionnaire [44]. A
secondary outcome measure for psychotic-like experi-
ences will be the 16-item version of the Prodromal Ques-
tionnaire [45]. A score of six or more has 87 % specificity
and 87 % sensitivity to correctly classify ultra-high risk for
psychosis mental states in a help-seeking sample [45]. The
measures to assess affective symptoms will be the Patient
Health Questionnaire (PHQ) nine-item version [46], the
Generalised Anxiety Disorder (GAD) seven-item version
[47], the PHQ four-item version for a brief mid-therapy
assessment [48], and the Altman Mania Scale [49].
To test the hypothesis concerning the potential develop-
ment of mental health disorders by 22 weeks, specifically
meeting criteria for ultra-high risk for psychosis, bipolar
affective disorder, depression, and anxiety, we will use
established cut-offs on the Prodromal Questionnaire [45],
Altman Mania Scale [49], PHQ [46], and GAD-7 [47], re-
spectively. Participants will be asked at each online assess-
ment time point (apart from week three) whether they are
in contact with mental health services, have received a
mental health diagnosis, take medication for a mental
health problem, or are currently receiving psychological
therapy. We will additionally administer the Warwick Ed-
inburgh Mental Wellbeing Scale [50], the Work and Social
Adjustment Scale [51], and gather information on the
demographics of the sample.
Assessment of safety
The likelihood of serious adverse events occurring during
this trial is low since CBT for insomnia has not been re-
ported to cause them. The intervention offered in the trial
has previously been tested in a randomised controlled trial
testing change in insomnia and no adverse outcomes were
reported [32]. We will record the occurrence of any ser-
ious adverse events in trial participants, defined as: all
deaths, suicide attempts, serious violent incidents, admis-
sions to secure units, and formal complaints about theonline intervention. Owing to the online nature of the as-
sessments and intervention, it is unlikely that the research
team will become aware of all such events. Adverse events
are likely to come to our attention only if we are contacted
by a trial participant. For participants concerned about
their mental health, a list of UK support services is pro-
vided on the study website. If a participant makes contact
via email or telephone then the clinical psychologist co-
ordinating the trial can advise on appropriate clinical
services.
Statistical analysis and sample size
Descriptive statistics within each randomised group will be
presented for baseline values. These will include counts
and percentages for binary and categorical variables, and
means and standard deviations, or medians with lower and
upper quartiles, for continuous variables, along with mini-
mum and maximum values and counts of missing values.
There will be no tests of statistical significance nor confi-
dence intervals for differences between randomised groups
on any baseline variable. Data distributions and all model
assumptions will be checked for all analyses. If model as-
sumptions are not met, data will either be transformed or
analysed using a non-parametric test, as appropriate.
The sample size was calculated on the basis of change in
psychotic experiences, since there will be a much larger
standardised mean difference for sleep than psychotic-like
experiences. Based on the standard deviations observed
from previous studies for the SCI (SD = 2.5) and the GPTS
(SD = 10.4) [32, 52], a total sample size of 2,614 (1,307 per
group) will provide 90 % power to detect a small effect
size with a standardised mean difference of 0.15 in
psychotic-like experiences (primary outcome), whilst ac-
counting for a high level of expected attrition (40 %).
After randomisation, participants will be analysed accord-
ing to their allocated treatment group, irrespective of what
treatment they actually receive. We will endeavour to ob-
tain full follow-up data on every participant to allow full
intention-to-treat analysis but we will inevitably experience
the problem of missing data due to withdrawal, loss to fol-
low up, or non-response questionnaire items. Data analysis
will be performed using a mixed-effect model for repeated
measures. The model will include treatment group, time,
treatment-by-time interaction, and baseline covariates. An
unstructured correlation matrix will be used to model the
within-subject error correlation structure. An appropriate
contrast will be specified to test for treatment efficacy be-
tween randomised groups for the primary outcome. We
will also perform various sensitivity analyses using imput-
ation methods to test whether the results are robust enough
to allow for different assumptions about the missing data.
The results from the trial will be prepared as comparative
summary statistics (difference in response rate or means)
with 95 % confidence intervals. All the tests will be done at
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reported in accordance with the Consolidated Standards of
Reporting Trials (CONSORT) 2010 statements [53, 54] and
Standard Protocol Item: Recommendations for Interven-
tional Trials (SPIRIT) [55, 56] guidelines.
We will use modern causal inference methods for medi-
ational analyses [57, 58]. This involves using parametric
regression models to test for mediation of the digital CBT
intervention on psychotic-like experiences through insom-
nia. Analyses will adjust for baseline measures of the me-
diator, outcomes, and putative measured confounders. We
will include repeated measurement of mediators and out-
comes to account for classical measurement error and
baseline confounding, and instrumental variable methods
(baseline covariate by randomization interactions as
potential instruments) to investigate the sensitivity of the
estimates to these problems and that of unmeasured con-
founding [57]. A full, detailed analysis plan, including
plans for any interim analysis, subgroup analysis, and sen-
sitivity analysis of the primary outcomes, will be prepared
and finalised before the analysis.
Discussion
There is growing interest in the role of sleep in the
occurrence of mental health problems. The clinical im-
plication is that improving sleep, using established inter-
ventions such as CBT, can lessen other mental health
disorders. For example, a recent trial protocol describes
a test of CBT to reduce the occurrence of depressive
symptoms [59]. Our focus is upon sleep and psychotic
experiences. The OASIS study has a strong mechanistic
element, aiming to show the causal role of sleep in para-
noia and hallucinations, as well as demonstrate the po-
tential wide-ranging clinical benefits of the easily
disseminated digital intervention. The study design ben-
efits from being administered online, allowing us to re-
cruit a large sample and limit researcher bias during the
conduct of the study. It will, however, recruit a fairly
homogenous sample of the population (university stu-
dents), and this will limit the generalizability of the
results. Nonetheless the study will still provide a strong
test of the principal hypothesis that insomnia is
a contributory causal factor in the occurrence of
psychotic-like experiences. The CBT programme makes
no reference to psychotic-like experiences and the tech-
niques used are those designed to improve sleep; hence,
there will be a clear manipulation of sleep, allowing
causal inferences to made about the relationship to
psychotic-like experiences.
Trial status
Recruitment will begin in March 2015. It is anticipated
that recruitment will be complete by March 2016, there-
fore trial results will become available in 2016.Abbreviations
CBT: Cognitive behaviour therapy; GAD: Generalised anxiety disorder
(questionnaire); GPTS: Green et al. paranoid thoughts scale (questionnaire);
PHQ: Patient health questionnaire; SCI: Sleep condition indicator
(questionnaire); SPEQ: Specific psychotic experiences questionnaire
(questionnaire).
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